Disease · MONDO_0005464

rhegmatogenous retinal detachment

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. rhegmatogenous retinal detachment. Diseases, record MONDO_0005464. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005464

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: rhegmatogenous retinal detachment; Open Targets
Open Targets ID: MONDO_0005464; Open Targets
NCI Thesaurus: C118755; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 2 of its 10 drugs, from ClinicalTrials.gov; Open Targets

Drugs10

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TAURURSODIOL	CHEMBL272427	Small molecule	Phase 3	ClinicalTrials.gov	2	2	0	Drugs and targets
URSODIOL	CHEMBL1551	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
PERFLUOROHEXYLOCTANE	CHEMBL5314588	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
TOPOTECAN	CHEMBL84	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
DENUFOSOL TETRASODIUM	CHEMBL1767407	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
XELAFASLATIDE	CHEMBL6068318	Protein	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
BRIMONIDINE TARTRATE	CHEMBL1200389	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
INFLIXIMAB	CHEMBL1201581	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
LAMIVUDINE	CHEMBL141	Small molecule	Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
SULFUR HEXAFLUORIDE	CHEMBL1796998	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets7

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRA2A	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 agonist	Phase 2	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 agonist	Phase 2	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 agonist	Phase 2	https://conductscience.org/library/genes/152	Drugs and targets
NR1H4	Bile acid receptor	1	Bile acid receptor FXR agonist	Phase 3	https://conductscience.org/library/genes/9971	Drugs and targets
P2RY2	P2Y purinoceptor 2	1	Purinergic receptor P2Y2 agonist	Phase 2	https://conductscience.org/library/genes/5029	Drugs and targets
TNF	Tumor necrosis factor	1	TNF-alpha inhibitor	Phase 2	https://conductscience.org/library/genes/7124	Drugs and targets
TOP1	DNA topoisomerase 1	1	DNA topoisomerase I inhibitor	Phase 2	https://conductscience.org/library/genes/7150	Drugs and targets

Trials14

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00972374	Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function	Phase 2	44	2013-04-24	Rhegmatogenous Macula-off Retinal Detachment	BRIMONIDINE TARTRATE	Its record names the disease	ClinicalTrials.gov
NCT03780972	A Study to Evaluate the Safety and Tolerability of ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal Detachment	Phase 1	14	2024-09-24	Rhegmatogenous Retinal Detachment - Macula Off	XELAFASLATIDE	Its record names the disease	ClinicalTrials.gov
NCT06818721	Intravitreal Topotecan for Prevention or Treatment of Proliferative Vitreoretinopathy in Retinal Detachment	Phase 2	394		Retinal Detachment Rhegmatogenous, Proliferative Vitreoretinopathy	TOPOTECAN	Its record names the disease	ClinicalTrials.gov
NCT05730218	A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal Detachment	Phase 2	136		Rhegmatogenous Retinal Detachment - Macula Off	XELAFASLATIDE	Its record names the disease	ClinicalTrials.gov
NCT06294847	Ursodeoxycholic Acid (UDCA) as a Neuroprotective Adjuvant Treatment to Rhegmatogenous Retinal Detachment Surgery	Phase 3	120		Retinal Detachment	URSODIOL	Its record names the disease	ClinicalTrials.gov
NCT04891991	Intravitreal Infliximab for Proliferative Vitreoretinopathy	Phase 2	66		Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy, Retinal Detachment	INFLIXIMAB	Its record names the disease	ClinicalTrials.gov
NCT05523869	Intravitreal Topotecan in the Repair of Rhegmatogenous Retinal Detachment with Proliferative Vitreoretinopathy	Phase 2	50		Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment	TOPOTECAN	Its record names the disease	ClinicalTrials.gov
NCT06425419	The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy	Phase 1	50		Proliferative Vitreoretinopathy, Proliferative Vitreo-Retinopathy, Rhegmatogenous Retinal Detachment	TOPOTECAN	Its record names the disease	ClinicalTrials.gov
NCT02185469	Corneal Endothelial Cell Loss After Pneumatic Retinopexy for the Repair of Primary Rhegmatogenous Retinal Detachment	Not applicable	30		Rhegmatogenous Retinal Detachment	SULFUR HEXAFLUORIDE	Its record names the disease	ClinicalTrials.gov
NCT02841306	Ursodeoxycholic Acid for Rhegmatogenous Retinal Detachment	Phase 1	26		Rhegmatogenous Retinal Detachment	URSODIOL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 14

See all 14 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
32408387	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005464

GET https://conductscience.org/api/diseases/v1/MONDO_0005464/drugs

API reference For AI assistants